



## Dexcom G6 Continuous Glucose Monitoring System Now Available Through Tricare Pharmacy Benefit

April 12, 2022

- Beginning mid-April, TRICARE® members will have faster and more convenient access to the Dexcom G6 Continuous Glucose Monitoring (CGM) System
- Dexcom G6 will be available as a brand-name formulary pharmacy benefit to military members, retirees and their families

SAN DIEGO – April 12, 2022 – [DexCom, Inc.](https://www.dexcom.com) (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G6 CGM System will be available to military members, their families and retirees with diabetes as a TRICARE® brand-name formulary pharmacy benefit.

Effective mid-April 2022, members with diabetes will be eligible for a Dexcom G6 through the military treatment facility pharmacies at zero copayment, the TRICARE® retail pharmacy network at a \$38 copayment per 30-day supply or through the mail order/home delivery at a copayment of \$34 per 90-day supply.\* Previously, Dexcom G6 was available through the TRICARE® medical benefit by durable medical equipment suppliers where copayment amounts could vary depending on the plan. The pharmacy benefit provides a faster process and more consistent copayments for members.

“We are thrilled to make Dexcom G6 more easily accessible to the many military members and their families who rely on TRICARE,” said Kevin Sayer, chairman, president and CEO of Dexcom. “With the pharmacy benefit, TRICARE beneficiaries with diabetes can use this game-changing technology to make informed, real-time decisions about their health with little to no out of pocket costs.”

Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device† or receiver, giving patients real-time glucose data without the need to prick their finger.‡ The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that allows patients to share their glucose data in real time with up to 10 followers.††

### About DexCom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit [www.dexcom.com](https://www.dexcom.com).

#### Media Contact

Investor Contact  
619-884-2118

#### Investor Contact

Sean Christensen  
858-203-6657

[James.mcintosh@dexcom.com](mailto:James.mcintosh@dexcom.com) [sean.christensen@dexcom.com](mailto:sean.christensen@dexcom.com)

\* A prior authorization is required for all CGM. Please see your provider for more information.

† For a list of compatible devices, visit [www.dexcom.com/compatibility](https://www.dexcom.com/compatibility).

‡ If your glucose alerts and readings from the G6 do not match symptoms or expectations or you're taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

†† Separate Follow App required.

© 2022 Dexcom, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. All rights reserved.